Search Results for “ obesity” – Page 22 – media

Withdrawal of financial incentives for NHS GPs in Scotland linked to reductions in quality of care

Ending performance-related payments for NHS GPs in Scotland was associated with a decline in the quality of some aspects of care compared with England where financial incentives have continued, finds a study published by The BMJ today. The researchers say further research is needed to better understand the full impact of withdrawal and the accompanying refocusing of quality improvement resources. The NHS Quality and Outcomes Framework (QOF) pay-for-performance scheme began in 2004. It was designed to remunerate general practices for providing good quality care across a range of key areas such as cancer, diabetes, heart disease, mental health, and obesity. In 2016, Scotland abolished the QOF to reduce the bureaucratic burden on GPs and to free-up their time for patients, but continued collecting performance data for some QOF indicators for the next three years. Researchers were therefore able to use this data to evaluate the impact of ...
- Source: drugdu
- 132
- April 24, 2023
Mediterranean diet may lower heart disease risk in women by nearly 25%, study finds

Closely following a Mediterranean diet may cut a woman’s risk of heart disease and death by nearly 25%, according to a new analysis of 16 studies. “This study adds to what is already known about the cardiovascular benefits of a Mediterranean diet but further reiterates that it can be equally as beneficial in women as it is known to be in men,” said lead author Sarah Zaman, associate professor at the Westmead Applied Research Centre at the University of Sydney, in an email. Heart disease is the number one killer of women and men worldwide, according to the World Health Organization. Coronary artery disease kills more than twice as many women as breast cancer in the United Kingdom, while in 2020, one in five deaths among women in the United States was because of heart disease. Yet few studies on the heart have looked specifically at women, ...
- Source: drugdu
- 109
- April 13, 2023
maker of Wegovy ‘skinny jab’ is funding NHS weight-loss services

The pharmaceutical company that makes Wegovy slimming jabs is funding the expansion of weight-loss services across England as it seeks to boost sales of its obesity drugs, the Observer can reveal. Novo Nordisk is paying the salaries of staff on NHS obesity teams and financing the launch and redesign of services, including giving £206,000 to a health partnership to transform its treatment of obesity. The Danish firm also has financial links to the co-chair of an NHS England weight management advisory group, and paid her almost £50,000 in lecture, consulting and other fees in just two years. Novo Nordisk’s funding arrangements are under the spotlight after an Observer investigation in March found it had paid £21.7m to UK health organisations and professionals in three years before the approval of its Wegovy injections for NHS use. In some cases, recipients of the funding went on to praise Wegovy or support its approval for use on the NHS without ...
- Source: drugdu
- 163
- April 4, 2023
Complications, pathophysiology, and treatment of type 2 diabetes differ by sex

In a recent review published in the journal Diabetologia, researchers in Austria discussed the sex-based differences in the risk factors, diagnosis, and therapeutic approaches for type 2 diabetes and associated complications to improve awareness about and management options for all diabetes type 2 patients. Background Studies show that patterns associated with type 2 diabetes vary according to sex, with the prevalence of the disease being higher among the young to middle-aged male population but the increase in postprandial glucose levels being higher among women and increasing with age. Furthermore, the varying clinical outcomes based on sex depend on the influence of hormonal and genetic factors on the diagnoses, therapeutic response, clinical outcomes, and pathophysiology. Therefore, because of the varying levels of sex hormones, the risk of type 2 diabetes and other cardiometabolic diseases also varies significantly for women. Additionally, substantial sex-based differences in lifestyles, behaviors, and approaches ...
- Source: drugdu
- 153
- March 28, 2023
Link found between late eating and higher consumption of ultra-processed foods

Bonaccio M, Ruggiero E, Di Castelnuovo A, et al. Association between Late-Eating Pattern and Higher Consumption of Ultra-Processed Food among Italian Adults: Findings from the INHES Study. Nutrients, 2023, DOI: 10.3390/nu15061497, https://www.mdpi.com/2072-6643/15/6/1497 In a recent study published in the journal Nutrients, researchers in Italy examined the associations between meal timing and food processing. Unhealthy diets are risk factors for obesity and related disorders. As such, strategies to tackle obesity have been focused on food compositions, resulting in recommendations to lower sugar, salt, and fat intake, with a concomitant increase in fiber, vitamin, and mineral intake. Much research has been centered on meal timing, with population studies implicating late eating in obesity and nutrition-related non-communicable diseases. Nonetheless, no study has investigated the relationship between meal timing and processed foods. About the study In the present study, researchers evaluated whether meal timing is associated with foods with different ...
- Source: drugdu
- 132
- March 28, 2023
The high price of Ozempic is pushing many to unregulated, copycat drugs for weight loss

Some compounding pharmacies are offering what they say are generic versions of the drugs, which have soared in popularity for weight loss. When Robin Langois, 58, was prescribed the weight-loss drug Wegovy last year, she couldn’t afford the high price tag after her insurance wouldn’t cover it. But she later discovered on TikTok that people could get their hands on what appeared to be the drug’s active ingredient, semaglutide, from compounding pharmacies for a fraction of the price. Langois, of Tucson, Arizona, said she was initially hesitant, because of safety concerns, but she eventually found a telehealth provider to write her a prescription. “I’m not 100% sure it’s what I’m getting,” Langois said. She noted, however, that she’s experienced feelings of fullness and weight loss, as well as nausea, a common side effect of the drug. “It’s working like it should,” she said. Either due to cost or ongoing shortages, ...
- Source: drugdu
- 168
- March 20, 2023
China’s Import and Export Market Report of Rheumatoid Arthritis Drugs

Rheumatoid arthritis (RA) is an autoimmune disease with complex pathogenesis and an extremely high morbidity rate, which seriously affects the quality of the life of patients and brings economic burden to society. Thus, effective treatments of RA has become a global concern of the pharmaceutical industry.
- Source: Ddu
- 3,944
- August 26, 2021
Ddu College Market Reports RA
Newly introduced Health and Care Bill aims to ‘dispose of unnecessary bureaucracy’

Health and Social Care Secretary Sajid Javid has introduced a new Health and Care Bill to parliament this week, containing proposals to ‘help the NHS build back better from the pandemic’. Earlier this year, the government revealed its proposed plans for the new Bill, with the formal introduction to parliament coming on the heels of ‘extensive’ discussion with NHS England, the Local Government Association and the health and care sector. Among the key measures outlined in the Bill includes plans to bring together the NHS and local government to plan health and care services. Other proposals include the development of a new procurement regime for the NHS and public health procurement, which aims to reduce bureaucracy on commissioners and providers alike. This proposal will also aim to reduce the need for competitive tendering, when it adds limited or no value. The Bill will also ensure that each part of England ...
- Source: drugdu
- 202
- July 7, 2021
Health and Care Bill
Novo Nordisk’s weight loss drug semaglutide found to improve wellbeing

New results from a Phase IIIa study have demonstrated that Novo Nordisk’s weight loss drug semaglutide improved physical function and wellbeing among people with obesity. The STEP 1 trial demonstrated benefits for people with obesity treated with semaglutide 2.4mg ‘beyond weight loss’, Novo said in a statement. Over a 68-week period, treatment with once-weekly semaglutide 2.4mg was associated with greater improvements for all weight- and health-related quality of life scores in people with obesity or overweight in comparison to placebo. This included improved wellbeing, with 43.8% of patients treated with Novo’s drug achieving a clinically meaningful improvement in total weight-related quality of life score at week 68. On top of that, 51.2% of participants treated with semaglutide 2.4mg in the trial had an increased weight-related physical function score, reflecting improvements in the ability to perform daily activities. In addition, patients treated with semaglutide 2.4mg ‘simultaneously’ experienced significant weight loss of ...
- Source: drugdu
- 460
- May 17, 2021
weight loss drug
Moderna’s Phase 3 COVE study for its COVID-19 vaccine

30 November 2020 The Phase 3 COVE trial is a randomized, 1:1 placebo-controlled study testing mRNA-1273 at the 100 µg dose level in 30,000 participants in the U.S., ages 18 and older. The primary endpoint is the prevention of symptomatic COVID-19 disease. Key secondary endpoints include prevention of severe COVID-19 disease and prevention of infection by SARS-CoV-2. The trial will continue to accrue additional data relevant to safety and efficacy even after an EUA is submitted. The final estimates of vaccine efficacy for both primary and secondary endpoints will depend on the totality of data that will accumulate to inform the final analysis. Moderna worked closely with BARDA and the NIH, including NIAID’s COVID-19 Prevention Network (CoVPN), to conduct the Phase 3 COVE study under Operation Warp Speed. Moderna’s partner PPD (Nasdaq: PPD), a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services, has ...
- Source: drugdu
- 160
- December 1, 2020
Covid-19 vaccine

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.